PMID- 36151599
OWN - NLM
STAT- MEDLINE
DCOM- 20221209
LR  - 20221209
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 110
IP  - 1
DP  - 2023 Jan
TI  - The association of age and adverse events of PEG-asparaginase in a pediatric 
      tertiary care hospital; a retrospective review.
PG  - 32-39
LID - 10.1111/ejh.13867 [doi]
AB  - BACKGROUND: Pediatric patients have a better survival rate for lymphoid 
      malignancies than adolescents and young adult patients (AYA) and current evidence 
      suggests that asparaginase plays a role in improved response to treatment. This 
      study aimed to evaluate if increasing age as a continuous variable demonstrated 
      increasing toxicities to PEG-asparaginase (PEG-ASP) for those patients treated at 
      a tertiary care pediatric hospital. METHODS: A retrospective chart review from 
      2007 to 2017 was conducted in the pediatric population at the Children's Hospital 
      of Eastern Ontario (CHEO). Patients having received PEG-ASP were included. Event 
      incidence and risk related to age at diagnosis were assessed through parameter 
      estimates and Wald chi-square analysis. RESULTS: In total, 75 adverse events were 
      observed: 34/186 (18.3%) experienced allergic reactions, 8/186 (4.3%) 
      pancreatitis, 31/186 (16.7%) thrombosis, and 2/186 (1.1%) hemorrhage. One hundred 
      and eighty two patients had complete information for inclusion in our model. A 
      correlation between age at diagnosis and higher risk of allergic reaction 
      (p < .001) and pancreatitis (p < .035) was observed. CONCLUSION: Allergic 
      reaction and pancreatitis following administration of PEG-ASP have a higher risk 
      of occurrence as age of diagnosis increases up to 18 years of age. This includes 
      the lower limit of traditionally defined AYA population of 15-39 and warrants 
      precaution as PEG-ASP is included in older populations treatment regimens at 
      pediatric centers.
CI  - (c) 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Abbott, Lesleigh
AU  - Abbott L
AD  - Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, 
      Ontario, Canada.
FAU - Claveau, Maia
AU  - Claveau M
AD  - Department of Pharmacy, Children's Hospital of Eastern Ontario, Ottawa, Ontario, 
      Canada.
FAU - Tang, Ken
AU  - Tang K
AD  - Research Institute, Children's Hospital of Eastern Ontario, Ottawa, Ontario, 
      Canada.
FAU - Cameron, Jameason
AU  - Cameron J
AD  - Department of Pharmacy, Children's Hospital of Eastern Ontario, Ottawa, Ontario, 
      Canada.
FAU - Goulet, Genevieve
AU  - Goulet G
AD  - Department of Pharmacy, Children's Hospital of Eastern Ontario, Ottawa, Ontario, 
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20221017
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Antineoplastic Agents)
RN  - EC 3.5.1.1 (Asparaginase)
RN  - 7D96IR0PPM (pegaspargase)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - Young Adult
MH  - *Antineoplastic Agents/therapeutic use
MH  - Asparaginase/adverse effects
MH  - *Hypersensitivity
MH  - *Pancreatitis/chemically induced/epidemiology
MH  - Polyethylene Glycols/adverse effects
MH  - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/epidemiology
MH  - Retrospective Studies
MH  - Tertiary Care Centers
OTO - NOTNLM
OT  - PEG-asparaginase
OT  - adolescent and young adults
OT  - adverse events
OT  - age
OT  - pegaspargase
OT  - side effects
EDAT- 2022/09/25 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/09/24 00:22
PHST- 2022/08/30 00:00 [revised]
PHST- 2022/01/27 00:00 [received]
PHST- 2022/09/08 00:00 [accepted]
PHST- 2022/09/25 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/09/24 00:22 [entrez]
AID - 10.1111/ejh.13867 [doi]
PST - ppublish
SO  - Eur J Haematol. 2023 Jan;110(1):32-39. doi: 10.1111/ejh.13867. Epub 2022 Oct 17.